Currently, there is limited evidence supporting ensartinib’s efficacy as a neoadjuvant treatment for locally advanced anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC). Here, ALK is linked to non-small cell lung carcinoma.